liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Novel therapies in the management of type I diabetes mellitus
Linköping University, Department of Clinical and Experimental Medicine, Pediatrics. Linköping University, Faculty of Health Sciences. Östergötlands Läns Landsting, Center of Paediatrics and Gynaecology and Obstetrics, Department of Paediatrics in Linköping.
2012 (English)In: Panminerva Medica (Testo stampato), ISSN 0031-0808, Vol. 54, no 4, 257-270 p.Article in journal (Refereed) Published
Abstract [en]

Development of insulin pumps and glucose sensors together with sophisticated algoritms and connections leading to closed loop systems will probably soon improve and facilitate treatment for many patients with Type 1 diabetes (T1D). However, the burden for patients will not disappear completely, and such therapy will still require both competence and motivation of patients. Therefore the final goal should be either to cure the disease via replacement therapy (transplantions) or stop the destructive process, preserve residual insulin secretion or even improve via beta cell regeneration. This will give a milder disease, a more stable metabolism, simpler treatment and perhaps even cure. It is neither necessary nor even plausible that Type 1 diabetes has one single cause or pathogenesis. Infections may be one causal factor, and vaccinations will then turn the increasing incidence downwards. We will also soon know whether it is possible to prevent some cases of T1D by avoiding cows milk in the early nutrition. It is possible that probiotics can influence the gut flora so that the gut permeability is normlized and maturation of the immune system is improved which may also contribute to less incidence of Type 1 diabetes. However, for those who already have got the disease we need interventions to preserve exisiting beta cell function and facilitate regeneration of beta-cells. Broader immunosuppressive therapies have been disappointing. Phase III studies using monocloncal antiCD3 antibodies have recently failed, but one dose regimen showed promising effect in patients aged 8-20 years. Therefore furthers studies are needed. Autoantigen treatment is a promising concept, and has the great advantage of being easy, practical with no adverse events. Diapep277 has shown some positive results in adults with good C-peptide, and glutamic acid decarboxylase (GAD)-alum has given quite impressive results in children aged 10-20 years, even though the results from studies differ. It is time to start combination therapies where auto-antigen/s, alone or in combination, are used together with other agents such as Vitamin D and anti-inflammatory drugs. We need to learn how to treat subgroups of patients. Gradually a more individualized treatment may become successful.

Place, publisher, year, edition, pages
Edizioni Minerva Medica , 2012. Vol. 54, no 4, 257-270 p.
Keyword [en]
Diabetes mellitus, type I; Antibodies, monoclonal; Vaccines, DNA; Autoantigens; Probiotics; C-peptide
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-87726ISI: 000312608400001PubMedID: 23123577OAI: diva2:600043
Available from: 2013-01-23 Created: 2013-01-22 Last updated: 2014-09-01Bibliographically approved

Open Access in DiVA

No full text


Search in DiVA

By author/editor
Ludvigsson, Johnny
By organisation
PediatricsFaculty of Health SciencesDepartment of Paediatrics in Linköping
In the same journal
Panminerva Medica (Testo stampato)
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 129 hits
ReferencesLink to record
Permanent link

Direct link